Stephen F. Lowry mostly deals with Immunology, Tumor necrosis factor alpha, Internal medicine, Cytokine and Endocrinology. His Tumor necrosis factor alpha research is multidisciplinary, incorporating perspectives in Lipopolysaccharide, Shock, Endogeny, Antibody and Mediator. His Internal medicine study deals with Gastroenterology intersecting with Parenteral Nutrition Solutions.
His Cytokine research is multidisciplinary, incorporating elements of Inflammation, Receptor, Autocrine signalling and Wound healing. His Endocrinology research includes themes of Cachexia and Monokine. His work in Septic shock covers topics such as Bacteremia which are related to areas like Necrosis.
His primary areas of investigation include Internal medicine, Endocrinology, Immunology, Tumor necrosis factor alpha and Cytokine. His Internal medicine study frequently links to related topics such as Gastroenterology. His Endocrinology research incorporates themes from Amino acid and In vivo.
His Immunology research focuses on Sepsis, Inflammation, Immune system, Innate immune system and Pathogenesis. His study in Tumor necrosis factor alpha is interdisciplinary in nature, drawing from both Lipopolysaccharide, Shock, Receptor, Interleukin and Mediator. His studies deal with areas such as Proinflammatory cytokine and Receptor antagonist as well as Cytokine.
The scientist’s investigation covers issues in Immunology, Inflammation, Internal medicine, Heart rate variability and Neuroscience. The various areas that Stephen F. Lowry examines in his Immunology study include Transcriptome and Signal transduction. Stephen F. Lowry has included themes like Receptor, Regulation of gene expression and Sepsis in his Inflammation study.
His studies in Sepsis integrate themes in fields like Bacteremia, Complication, Incidence and Intensive care medicine. His research integrates issues of Score test, Multiple comparisons problem, Endocrinology and Oncology in his study of Internal medicine. Stephen F. Lowry studied Endocrinology and In vivo that intersect with Cytokine and Splanchnic.
His primary areas of study are Inflammation, Immunology, Sepsis, Neuroscience and Heart rate variability. His research investigates the connection between Inflammation and topics such as Signal transduction that intersect with problems in Extracellular and Pharmacology. His Immunology study incorporates themes from Regulation of gene expression and Homeostasis.
His Sepsis study is concerned with the field of Surgery as a whole. His Circadian rhythm study combines Internal medicine and Endocrinology studies. His Internal medicine study often links to related topics such as In vivo.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Shock and tissue injury induced by recombinant human cachectin.
Kevin J. Tracey;Bruce A Beutler;Stephen F. Lowry;James Merryweather.
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Kevin J. Tracey;Kevin J. Tracey;Yuman Fong;David G. Hesse;Kirk R. Manogue.
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok Junhee Seok;Shaw Warren H. Shaw Warren;G. Cuenca Alex;N. Mindrinos Michael.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Charles J. Fisher;Jan M. Agosti;Steven M. Opal;Stephen F. Lowry.
The New England Journal of Medicine (1996)
A network-based analysis of systemic inflammation in humans
Steve E. Calvano;Wenzhong Xiao;Daniel R. Richards;Ramon M. Felciano.
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Charles J. Fisher;Jean-Francois A. Dhainaut;Steven M. Opal;John P. Pribble.
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group
Steven M. Opal;Charles J. Fisher;Jean-Francois A. Dhainaut;Jean-Louis Vincent.
Critical Care Medicine (1997)
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
K J Van Zee;T Kohno;E Fischer;C S Rock.
Proceedings of the National Academy of Sciences of the United States of America (1992)
A genomic storm in critically injured humans
Wenzhong Xiao;Wenzhong Xiao;Michael N. Mindrinos;Junhee Seok;Joseph Cuschieri.
Journal of Experimental Medicine (2011)
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.
Y Fong;K J Tracey;L L Moldawer;D G Hesse.
Journal of Experimental Medicine (1989)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: